CD19 and hematopoietic and lymphoid cell neoplasm: NK cells and CAR T cells have been demonstrated to show the highest efficiency against hematological cancer.33 34 Patients with B cell malignancies are today typically treated with therapies targeting CD20 or CD19, commonly using antibody therapies targeting CD20, Rituximab and Ofatumumab, or CD19 directed CAR T cells.